← Oncology Approval Tracker

FDA DECISION ·

Kyprolis + Sarclisa + dexamethasone

carfilzomib plus isatuximab-irfc and dexamethasone · Onyx Therapeutics / Amgen

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The Isa-Kd regimen for adults with relapsed or refractory multiple myeloma following one to three previous therapy lines.

LAMPGEN ANALYSIS

Why it matters

The decision adds the isatuximab-based regimen to the carfilzomib label.

What research teams should watch

Document the prior-line count and coordinate administration and monitoring for the individual regimen components.

PRIMARY RECORDS

Sources